- Home
- FULC
as 03-28-2025 4:00pm EST
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 210.9M | IPO Year: | 2019 |
| Target Price: | $6.57 | AVG Volume (30 days): | 465.5K |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.78 - $10.13 | Next Earning Date: | 05-12-2025 |
| Revenue: | $80,000,000 | Revenue Growth: | 2752.05% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Simply Wall St.
a month ago
Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
GuruFocus.com
a month ago
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 Fulcrum Therapeutics Inc Earnings Call
GlobeNewswire
a month ago
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
GuruFocus.com
a month ago
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result
GlobeNewswire
a month ago
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
GlobeNewswire
2 months ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare FULC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.